Answers are grounded in this paper and cite their sources.
Moringa oleifera Lam. is a widely cultivated food and medicinal tree whose leaves are consumed as a vegetable, powder or infusion across tropical and subtropical regions and are increasingly marketed as supplements with claimed anticancer benefits. The experimental literature on leaf preparations has expanded rapidly, yet existing reviews frequently pool evidence from leaves, seeds, roots, pods and green-synthesised metal nanoparticles, and rarely interrogate potency, extract characterisation or translational plausibility. This critical narrative review evaluates the evidence for anticancer activity of M. oleifera leaves, with particular attention to the phytochemical basis of activity, the robustness of proposed mechanisms and the gap between preclinical findings and therapeutic application. Peer-reviewed literature was identified through structured searches of biomedical and multidisciplinary scholarly indexes, a clinical trial registry and citation tracking, and was appraised qualitatively for botanical specification, chemical characterisation, model validity, mechanistic rigour and translational relevance. The leaf contains a distinctive glucosinolate–myrosinase system yielding rhamnosylated benzyl isothiocyanates, alongside abundant flavonol glycosides, caffeoylquinic acids, polysaccharides, peptides and minor alkaloids. Crude and fractionated leaf extracts consistently reduce the viability of diverse cancer cell lines through oxidative stress, mitochondrial apoptosis, cell-cycle arrest and suppression of inflammatory and oncogenic signalling, and several rodent studies report chemopreventive effects. Most crude aqueous and ethanolic extracts, however, act only at concentrations that fall in the moderate-to-weak range of accepted cytotoxicity benchmarks, few studies authenticate or chemically standardise the material tested, and the dominant isothiocyanate has been studied chiefly in seed-derived form. Human pharmacokinetic data for leaf isothiocyanates are absent, no registered oncology trial was identified, a clinically measurable herb–drug interaction has been demonstrated in volunteers, and one preclinical study found that a moringa seed extract worsened tumour progression when combined with chemotherapy. The current evidence supports M. oleifera leaves as a source of chemopreventive and immunomodulatory leads and as a candidate dietary adjunct requiring safety evaluation, not as a demonstrated cancer therapy. Standardised, chemically characterised leaf preparations, pharmacokinetically informed dosing and carefully designed early-phase human studies are the immediate priorities.
No takes yet. Share an insight, caveat, or question.
Pawar et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: